摘要
目的:研究以罗非昔布、塞来昔布、伐地昔布、鲁米昔布为代表的选择性COX-2抑制剂在临床应用的安全性。方法:查询国内外相关文献资料并结合临床实践进行回顾性研究。结果:罗非昔布、塞来昔布、伐地昔布、鲁米昔布等都有增加心血管不良事件的危险,同时罗非昔布的心血管风险要高于塞来昔布。结论:心血管危险是COX-2抑制剂的“类效应,”所以在临床应用这类药物时,应当加强合理的监管措施;仍需对COX-2抑制剂在心血管系统的安全性进行深入研究。
Objective： To study the clinical safety of selective cyclooxygenase-2 inhibitors which mainly include rofecoxib, celecoxib, valdecoxib and lumiracoxib. Methods： The related literatures were searched for and analyzed retrospectively with clinical practice. Resuits： The selective cyclooxygenase-2 inhibitors including rofecoxib, celecoxib, valdecoxib and lumiracoxib could increase the risk of cardiovascular event and the risk of rofecoxib was higher than celecoxib. Conclusion： Cardiovascular risk is of class effect of the selective cycloox.vgenase-2 inhibitors. Supervision of them in clinical use should be intensified and the cardiovascular safety of these drugs should be investigated further.
出处
《儿科药学杂志》
CAS
2005年第5期6-8,共3页
Journal of Pediatric Pharmacy
